沙特阿拉伯BNT162b2疫苗接种后急性非 solicited 不良事件的真实世界数据
在沙特阿拉伯利雅得社区疫苗接种中心,对2021年3月31日前接种BNT162b2疫苗的16岁以上人群接种后30分钟内的急性不良事件进行回顾分析,共71,221名接种者中144人报告345起急性不良事件,发生率为每10,000剂48.4起,多为非严重事件,女性与任何急性不良事件发生显著相关,未记录到高度确定性的过敏反应病例或死亡。
要点
- 71,221名接种者中144人发生345起急性不良事件,发生率为每10,000剂48.4起。
- 女性与任何急性不良事件发生显著相关(P=0.002)。
- 未记录到高度确定性过敏反应病例,无死亡,仅1/144因非过敏反应原因住院。
核心结论
- BNT162b2疫苗引起的急性不良事件罕见且多为非严重,有在女性中更常发生的倾向。
- 作者认为需要在更大队列的接种者中开展进一步前瞻性研究以评估沙特人群中过敏反应的发生率。
研究设计与样本
- 回顾性分析2021年3月31日前在沙特阿拉伯利雅得社区疫苗接种中心接种BNT162b2疫苗的16岁以上人群,接种后30分钟内的急性不良事件(AAE组)。
- 采用Brighton合作组疫苗安全性病例定义定义过敏反应,收集人口学、合并症、过敏史和转归情况,接种后观察时长分为短(<15分钟)或延长(<3小时)。
主要发现
- 71,221名接种者中144人(0.002%)发生345起急性不良事件,发生率为每10,000剂48.4起。
- AAE组大多数为第一剂接种者(93.8%)和既往健康者(59%),少数有过敏史(6.3%)或实验室确诊COVID-19史(4.2%)。
- 女性与任何急性不良事件发生显著相关(P=0.002)。
- 每10,000剂中非过敏反应性急性不良事件:头晕17.8、头痛9.7、恶心7.1、晕厥3.2。
- 每10起急性不良事件中仅1起被认为是严重并导致延长观察(每10,000剂4.8起),仅1/144因非过敏反应原因需住院(每10,000剂0.1起)。
关键数值与推荐
- 采用Brighton合作组过敏反应病例定义,未记录到任何高度确定性过敏反应病例。
- 本队列未记录到死亡。
局限性
- 接种后观察时长较短(<15分钟)或延长(<3小时)。
- 作者认为需要在更大队列的接种者中开展进一步前瞻性研究以评估沙特人群中过敏反应的发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute adverse events and anaphylaxis were reported after the administration of coronavirus disease (COVID-19) mRNA vaccines. We aim to explore the nature and outcome of adverse events following BNT162B2 vaccine in a community vaccination center, Riyadh, Saudi Arabia. METHOD: Within 30 min post vaccination, all acute adverse events (AAEs) that occurred before March 31st, 2021, and in people older than 16 years were reviewed (AAE group). We used the case definition of Brighton collaboration on vaccine safety to define anaphylaxis. Patients' demographics, comorbidities, allergy history, and outcome at disposition were collected. Observation duration after vaccination was short (<15 min) or extended (<3 h). Statistical analysis was performed to study AAEs association with the study variables and outcomes. RESULTS: Out of 71,221 vaccine recipients, 144 (0.002%) had developed 345 AAEs, at a rate of 48.4 events per 10,000 dose administered. The majority of cases in AAE group were first dose recipients (93.8%) and previously healthy (59%), while the minority had a previous history of allergy (6.3%) or a laboratory-confirmed COVID-19 (4.2%). We found a significant association between female gender and the occurrence of any AAE (p-value = 0.002). Per every 10,000 doses administered, non-anaphylactic AAEs were dizziness (17.8), headache (9.7), nausea (7.1), or syncope (3.2). Only one in every ten AAEs was considered serious and resulted in an extended observation (4.8 per 10,000 doses), but only 1/144 required hospitalization for non-anaphylaxis reasons (0.1 per 10,000 doses). According to the Brighton collaboration definition of anaphylaxis, no single case of high certainty anaphylaxis was recorded. No death was documented in this cohort. CONCLUSION: Acute adverse events due toBNT162b2 vaccinewere rare andmostlynon-seriouswith a tendency to occur more in women. Further prospectivestudieson largervaccine recipientsto evaluatethe incidenceof anaphylaxis in the Saudi population are warranted.
引用
- Almohaya AM, Alsubie H, Alqarni B, et al. Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data. Vaccine. 2021. PMID: 34916104. doi:10.1016/j.vaccine.2021.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。